Comparison of the Effectiveness and Hypocalcemia Risk of Antiresorptive Agents in Patients with Hypercalcemia of Malignancy
Background Hypercalcemia of malignancy (HCM), a major metabolic complication of cancer, is often managed with bisphosphonates (BP) and, increasingly, with denosumab. We aimed to compare the effectiveness and safety of denosumab with that of BP, with or without calcitonin, in treating HCM. Methods Th...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Korean Endocrine Society
2025-04-01
|
| Serie: | Endocrinology and Metabolism |
| Soggetti: | |
| Accesso online: | http://e-enm.org/upload/pdf/enm-2024-2132.pdf |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|